Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Gilead Sciences Inc (NASDAQ:GILD)

72.70
Delayed Data
As of Dec 09
 +0.68 / +0.94%
Today’s Change
70.83
Today|||52-Week Range
104.79
-28.15%
Year-to-Date
GILD Regular Dividend: GILD will begin trading ex-dividend on 12/13/16 with a $0.47 dividend payable to shareholders of record as of 12/15/16.
10 Stocks for Using a Benjamin Graham Value Investing Strategy
Dec 09 / GuruFocus News - Paid Partner Content
3 Beaten-Up Healthcare Stocks: Are They Bargains?
Dec 06 / MotleyFool.com - Paid Partner Content
Top Research Reports for NVIDIA, Medtronic & Gilead Sciences
Dec 09 / Zacks.com - Paid Partner Content
5 Companies for Enterprising Investors Near 52-Week Lows
Dec 05 / GuruFocus News - Paid Partner Content
This May Be 2016's Top Stock-Selection Model
Dec 08 / TheStreet.com - Paid Partner Content
10 Low P/E Picks for the Enterprising Investor
Dec 05 / GuruFocus News - Paid Partner Content
I'm Buying Biotech on This Trump Scare
Dec 08 / TheStreet.com - Paid Partner Content
1 Quote Reveals Why Gilead Sciences Hasn't Bought Anybody Yet
Dec 05 / MotleyFool.com - Paid Partner Content
Gilead Sciences Inc.'s Worst Moves in 2016
Dec 06 / MotleyFool.com - Paid Partner Content
NHS to launch three-year anti-HIV PrEP trial
Dec 04 / FT.com - Paid Partner Content

Today’s Trading

Previous close72.02
Today’s open72.34
Day’s range71.95 - 73.13
Volume9,936,284
Average volume (3 months)9,679,920
Market cap$95.8B
Dividend yield2.59%
Data as of 4:00pm ET, 12/09/2016

Growth & Valuation

Earnings growth (last year)+62.04%
Earnings growth (this year)-9.30%
Earnings growth (next 5 years)-4.00%
Revenue growth (last year)+28.71%
P/E ratio6.8
Price/Sales4.80
Price/Book5.58

Competitors

 Today’s
change
Today’s
% change
AMGNAmgen+2.86+2.03%
BIIBBiogen-1.77-0.61%
ILMNIllumina Inc-0.28-0.23%
TECHBio-Techne Corp-0.54-0.50%
Data as of 4:14pm ET, 12/09/2016

Financials

Next reporting dateFebruary 8, 2017
EPS forecast (this quarter)$2.60
Annual revenue (last year)$32.0B
Annual profit (last year)$18.1B
Net profit margin56.52%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
John F. Milligan
Chief Operating Officer
Kevin B. Young
Corporate headquarters
Foster City, California

Forecasts


Search for Jobs